RNAC Stock Forecast & Price Target

Cartesian Therapeutics is an emerging leader in the development of cell therapies for autoimmune diseases. Their RNA based approach offers numerous advantages over traditional DNA-based therapies, such as lower cost and improved safety. With a solid cash position and positive clinical trial data in the treatment of dermatomyositis, the company is well-positioned to drive future growth and continue its research into other autoimmune disorders.

Cartesian Therapeutics is currently trading at an unusually low EV of ~$50M, despite having a registrational Phase 3 program with a high likelihood of success, backed by Phase 2 data and a clean safety profile. Their primary driver, Phase III AURORA, is expected to read out by mid-2027 and could have further upside potential from a pediatric trial in juvenile dermatomyositis. With ~$145M in cash and a potential market opportunity of ~100,000 MG patients, the current valuation seems disproportionate to the commercial opportunity and degree of clinical risk-mitigation for this biopharmaceutical company.